Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS: INTI · Delayed Price · USD
0.0700
0.00 (0.00%)
Mar 25, 2024, 1:09 PM EDT - Market closed

Inhibitor Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019201820172016201520142013 2012 - 1996
Revenue
00000000-0.030
Upgrade
Gross Profit
00000000-0.030
Upgrade
Selling, General & Admin
0.650.320.871.541.932.894.382.271.510.82
Upgrade
Research & Development
0.0100.191.212.632.232.641.682.431.07
Upgrade
Operating Expenses
0.660.331.062.754.565.127.023.953.941.88
Upgrade
Operating Income
-0.66-0.33-1.06-2.75-4.56-5.12-7.02-3.95-3.94-2
Upgrade
Interest Income
0000.010.010.020.02000
Upgrade
Interest Expense
0.020.010000000.040
Upgrade
Other Expense / Income
-12.84-0.04--0.010.020.02---
Upgrade
Pretax Income
12.16-0.3-1.06-2.73-4.55-5.1-7-3.95-3.98-1.84
Upgrade
Income Tax
0.060.01-0-0.01-0.01-0.02-0.0200-0.17
Upgrade
Net Income
12.11-0.31-1.06-2.72-4.55-5.1-7-3.95-3.98-1.84
Upgrade
Shares Outstanding (Basic)
3663763723703703672892339618
Upgrade
Shares Outstanding (Diluted)
3683763723703703672892339618
Upgrade
Shares Change
-2.25%1.16%0.40%0.17%0.87%26.97%24.13%142.60%434.46%31.47%
Upgrade
EPS (Basic)
0.03-0.00-0.00-0.01-0.01-0.01-0.02-0.02-0.04-0.10
Upgrade
EPS (Diluted)
0.03-0.00-0.00-0.01-0.01-0.01-0.02-0.02-0.04-0.10
Upgrade
Free Cash Flow
11.74-0.22-0.83-2.71-3.71-2.91-3.76-2.26-1.3-1.22
Upgrade
Free Cash Flow Per Share
0.03-0.00-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.07
Upgrade
Effective Tax Rate
0.45%---------
Upgrade
EBITDA
-0.66-0.33-1.06-2.75-4.56-5.12-7.02-3.95-3.94-1.88
Upgrade
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.